company background image
BMKD.F logo

Biomark Diagnostics OTCPK:BMKD.F Stock Report

Last Price

US$0.22

Market Cap

US$18.5m

7D

3.9%

1Y

54.4%

Updated

21 Mar, 2024

Data

Company Financials

Biomark Diagnostics Inc.

OTCPK:BMKD.F Stock Report

Market Cap: US$18.5m

BMKD.F Stock Overview

Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment.

BMKD.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Biomark Diagnostics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biomark Diagnostics
Historical stock prices
Current Share Price€0.22
52 Week High€0.25
52 Week Low€0.12
Beta-0.080
1 Month Change11.47%
3 Month Change24.72%
1 Year Change54.40%
3 Year Change-35.84%
5 Year Change474.17%
Change since IPO-34.93%

Recent News & Updates

Recent updates

Shareholder Returns

BMKD.FUS BiotechsUS Market
7D3.9%0.08%1.9%
1Y54.4%11.6%31.1%

Return vs Industry: BMKD.F exceeded the US Biotechs industry which returned 12.6% over the past year.

Return vs Market: BMKD.F exceeded the US Market which returned 31.2% over the past year.

Price Volatility

Is BMKD.F's price volatile compared to industry and market?
BMKD.F volatility
BMKD.F Average Weekly Movementn/a
Biotechs Industry Average Movement11.8%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: BMKD.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine BMKD.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014n/aRashid Ahmed Buxhttps://www.biomarkdiagnostics.com

Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It holds an agreement with National Research Council of Canada Industrial Research Assistance Program to support research and development of liquid biopsy assay for the early detection and screening of lung cancer; and strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for women with dense breasts. The company was incorporated in 2014 and is headquartered in Richmond, Canada.

Biomark Diagnostics Inc. Fundamentals Summary

How do Biomark Diagnostics's earnings and revenue compare to its market cap?
BMKD.F fundamental statistics
Market capUS$18.45m
Earnings (TTM)-US$1.14m
Revenue (TTM)US$120.52k

153.1x

P/S Ratio

-16.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BMKD.F income statement (TTM)
RevenueCA$163.16k
Cost of RevenueCA$0
Gross ProfitCA$163.16k
Other ExpensesCA$1.70m
Earnings-CA$1.54m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.017
Gross Margin100.00%
Net Profit Margin-942.37%
Debt/Equity Ratio-166.4%

How did BMKD.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.